Merck Says Topline Data From Phase 2b/3 BRUNELLO Trial Of Remigromig (MK-3000, Formerly EYE103) For Diabetic Macular Edema Met Its Primary Endpoint
Key takeaways
- Remigromig meets Phase 3 non‑inferiority in DME, opening a new therapeutic avenue for patients who do not fully respond to existing anti‑VEGF drugs.
- 52 weeks
- 0.5 mg remigromig
- 0.8 mg remigromig
What happened
Merck announced that its investigational drug remigromig (MK‑3000, formerly EYE103) met the primary endpoint of the Phase 2b/3 BRUNELLO trial for diabetic macular edema. At 52 weeks, both 0.5 mg and 0.8 mg doses were non‑inferior to 0.5 mg ranibizumab on mean change from baseline in best‑corrected visual acuity. The drug was generally well tolerated, though higher rates of proliferative diabetic retinopathy, vitreous hemorrhage, and treatment discontinuations due to adverse events were seen…
Why it matters
DME is a leading cause of vision loss in diabetes, and current anti‑VEGF therapies leave up to 40 % of patients with incomplete response. Remigromig offers a first‑in‑class mechanism—activating the Wnt pathway—to potentially fill this unmet need. Demonstrating non‑inferiority to ranibizumab in a pivotal trial…
Short-term and longer-term
Short-term. Short‑term traders should watch the upcoming AAO presentation on Oct 10 for any new efficacy or safety details that could influence the stock’s volatility.
Longer-term. Long‑term investors should note that remigromig represents Merck’s first novel mechanism in retinal disease in over two decades, potentially diversifying its ophthalmology pipeline.